Vfend Patent Expiration

Vfend is a drug owned by Pf Prism Cv. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 29, 2022. Details of Vfend's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6632803 Pharmaceutical formulations containing voriconazole
Jun, 2018

(6 years ago)

Expired
US5567817 Triazole antifungal agents
May, 2016

(8 years ago)

Expired


FDA has granted several exclusivities to Vfend. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vfend, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vfend.

Exclusivity Information

Vfend holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Vfend's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jan 29, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Vfend is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vfend's family patents as well as insights into ongoing legal events on those patents.

Vfend's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Vfend's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 29, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Vfend Generics:

Voriconazole is the generic name for the brand Vfend. 23 different companies have already filed for the generic of Vfend, with Rising having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vfend's generic

How can I launch a generic of Vfend before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Vfend's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Vfend's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Vfend -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
200 mg/vial 12 Sep, 2008 1 30 May, 2012 02 Jun, 2018 Eligible
40 mg/mL 08 Oct, 2010 1 28 May, 2013 24 May, 2016 Eligible
50 mg and 200 mg 14 Apr, 2008 1 22 Apr, 2010 24 May, 2016 Eligible

Alternative Brands for Vfend

Vfend which is used for treating fungal infections., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch
Luzu Used for treating fungal infections.
Sebela Ireland Ltd
Naftin Used for treating fungal infections.
Vicuron Holdings
Eraxis Used for treating fungal infections.





About Vfend

Vfend is a drug owned by Pf Prism Cv. It is used for treating fungal infections. Vfend uses Voriconazole as an active ingredient. Vfend was launched by Pf Prism Cv in 2002.

Approval Date:

Vfend was approved by FDA for market use on 24 May, 2002.

Active Ingredient:

Vfend uses Voriconazole as the active ingredient. Check out other Drugs and Companies using Voriconazole ingredient

Treatment:

Vfend is used for treating fungal infections.

Dosage:

Vfend is available in the following dosage forms - for suspension form for oral use, tablet form for oral use, injectable form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
200MG/VIAL INJECTABLE Prescription INTRAVENOUS
50MG TABLET Prescription ORAL
200MG TABLET Prescription ORAL
200MG/5ML FOR SUSPENSION Prescription ORAL